FDA is gathering public comments for a 2026 report on patient-safety best practices related to certain “non-device” software functions under the 21st Century Cures Act—an issue that matters when AI-enabled tools provide clinical recommendations. Comments are due August 13, 2026.
FDA updated its AI-Enabled Medical Devices list on June 16, 2026. Here’s how patients, caregivers, and clinician-adjacent readers can check whether an AI-enabled medical device is FDA-authorized—and what the list and linked FDA entries do (and don’t) tell you.
A June 17, 2026 Federal Register final order codified a Class II (“special controls”) pathway for certain AI/ML radiology quantitative imaging software that uses an FDA-authorized Predetermined Change Control Plan (PCCP). In plain terms: when AI software updates are planned and bounded, FDA expects evidence, risk controls, and labeling—so clinicians can better understand when performance may change and how to verify results.
If a clinic says it uses AI, ask for the tool’s exact name and maker, then check FDA public records and ask who reviews the output before care decisions are made.
A June 2026 JAMA Pediatrics survey found that nearly 1 in 5 U.S. adolescents and young adults had used an AI chatbot for mental health advice, and most users said they had told no one. The study does not prove chatbots help or harm mental health, but it raises practical questions about privacy, oversight, and when parents should bring in a human professional.
A new study on FDA-authorized AI-enabled medical devices suggests a simple takeaway: ask whether the tool is FDA-authorized, whether a clinician reviews the result, and how you would learn about a recall or safety alert.
CMS’s WISeR model is active for selected Original Medicare services in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. Here is what it does, who it affects, and what patients should ask if care is delayed.
The FDA is pushing medical AI toward more transparent testing and stronger follow-up after a device reaches real-world care. That matters because AI tools can behave differently once they are used in busy clinics, with different patients, workflows, and data than they saw during development. For patients and families, the key question is not whether AI is present, but whether it is a regulated medical device, how it was evaluated, and what happens if its performance changes over time.
CMS is pushing electronic prior authorization toward wider use, with early adopters moving ahead before 2027 requirements. For patients, the promise is less faxing and fewer back-and-forth delays, but the rollout will be uneven and faster decisions are not guaranteed.
The FDA’s January 2026 guidance on clinical decision support software may make it clearer which AI tools fall outside device regulation and which still count as medical devices. That matters because AI is already appearing in triage, imaging, medication support, and administrative workflows. The main safety question is not whether AI can help. It is when a human still has to review the output, what the tool was validated for, and how errors are handled.
The FDA is moving toward clearer labeling for AI-enabled medical devices, especially in cardiology. The goal is simple: help patients and clinicians understand what the software does, who is overseeing it, and what is known about its performance before they decide how much to trust it.
Federal health agencies are embracing artificial intelligence, but they are pairing that adoption with caution. The practical message for patients and caregivers is simple: AI may be part of care, but the safety and usefulness of any tool depend on the specific device, setting, and oversight behind it.
FDA-authorized medical AI is already common in scans and workflow tools. Here’s what authorization means, what it does not, and what patients should ask.
Some medical AI tools are FDA-regulated, but authorization is not a promise of equal accuracy in every clinic. Here’s what patients should ask.
New U.S. polling shows many people already ask AI about symptoms and test results. Here’s where it can help, where it can mislead, and when to get human care.
CMS has started a limited Original Medicare pilot in six states that uses technology vendors and clinician review for a narrow set of services. Here’s what WISeR does, what has not changed, how reviews and appeals work, and why some experts worry about delays.
If your clinician says an AI tool will listen to the visit and draft the note, the newest U.S. evidence suggests modest paperwork savings for clinicians, not a proven transformation of care. Here is what these tools do, what remains uncertain, and what patients should ask about privacy, accuracy, and opt-out choices.
AI tools are increasingly used in imaging, diagnostics, and clinical decision support. Here’s how the FDA regulates artificial intelligence as medical devices, what Software as a Medical Device (SaMD) means, and what patients should know about safety, updates, and limits in 2026.
Artificial intelligence is increasingly used in imaging, heart monitoring, and disease screening. Here’s how the U.S. Food and Drug Administration regulates AI-enabled medical devices — and what that oversight means for patient safety, transparency, and trust.
Medicare Advantage plans and other insurers increasingly use algorithms to review prior authorization and claims. Federal watchdog findings and new CMS rules clarify what’s allowed, what isn’t, and what rights patients have when care is denied.
AI tools are increasingly used in U.S. hospitals and clinics, but not all of them are regulated the same way. Here’s how the FDA oversees AI-enabled medical devices, what clearance really means, and what patients should ask when AI is involved in their care.
Artificial intelligence is now built into many parts of U.S. healthcare, from imaging to insurance reviews. Here’s what federal agencies say about safety and oversight—and what patients should know before relying on AI tools.
End of content
End of content
